Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce ...

RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

< Exposure process: a USP laser writes a fiber Bragg grating into a fiber with a core diameter of 100 ... Fraunhofer ILT, Aachen, Germany / Volker Lannert.

Atomic clocks are more accurate than those used to define the second, suggesting the definition might need to change ...

Microsoft scientists have created a quantum processor that taps into a rare state of matter that was first theorized in the ...